The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.
John McDonough announced he is moving into an executive chairman role and will step down as CEO. The firm has begun searching for a new CEO.
Much of the growth was driven by contributions from Genoptix, which NeoGenomics acquired in late 2018. Organically, revenues were up 20 percent.
The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.
With the firm seeing lower profitability in diagnostics, its CEO said it is focusing on improving earnings strength with the Atellica Solution IVD platform.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
LabCorp Diagnostics was down 2.8 percent, while Covance Drug Development was up 8 percent. The firm narrowed its revenue and earnings guidance for the year.
Qiagen reported year-over-year net sales of 1 percent, or 5 percent at constant exchange rates ahead of its planned Q2 earnings release next week.
The lab beat the consensus Wall Street estimate on the top and bottom line, and maintained its revenue and adjusted EPS guidance for full-year 2019.
Danaher's life sciences revenues grew 6 percent, while its diagnostics revenues rose nearly 5 percent, including an increase of more than 20 percent at Cepheid.